Calypso Medical Partners with Siemens Healthcare in Master Development Agreement to Provide Better Control of Radiation Beam During Cancer Treatment

Tue Nov 3, 2009 9:15am EST

* Reuters is not responsible for the content in this press release.

Combined Technology Platforms May Lead to More Accurate Radiation Delivery and
Fewer Side Effects 
SEATTLE--(Business Wire)--
Calypso Medical Technologies, Inc., a developer of real-time localization
technology used for the precise tracking of tumor targets, today announced that
it has entered into a strategic development agreement with Siemens Healthcare to
jointly develop products integrating the Calypso® System with the Siemens
ARTISTE linear accelerator and other Siemens radiotherapy technologies. 

"Siemens` product offerings and leadership in the radiotherapy market are
world-class. By combining Calypso`s technology platform with cutting edge
Siemens products, we will be well-positioned to develop advanced radiation
therapy technologies," said Eric R. Meier, president and chief executive officer
of Calypso Medical. "This agreement will provide the framework for joint
development of real-time multi-leaf collimater (MLC) tracking, a future
capability* which will significantly enhance the delivery of radiation to
difficult-to-treat areas such as the pancreas and lung, as well as for our
current prostate cancer patients." 

Calypso and Siemens have already demonstrated the feasibility of MLC tracking
through a partnership with the German Cancer Research Center (Deutsches
Krebsforschungszentrum, DKFZ), the largest biomedical research institute in
Germany. MLC tracking enables the radiation beam to move in concert with the
tumor target based on real-time tracking data provided by the Calypso System,
thereby enabling faster, more precise delivery of radiation with a higher degree
of accuracy and confidence. 

"MLC tracking guided by the Calypso System can maximize treatment efficiency
while ensuring pinpoint delivery of radiation to the tumor, even in the presence
of significant tumor motion," said Uwe Oelfke, MCCPM, FInstP, professor of
medical radiation physics at the German Cancer Research Center (DKFZ). 

"We are very pleased with the MDA with Calypso Medical as this will allow us to
more rapidly develop new approaches for the delivery of radiation therapy," said
Holger Schmidt, chief executive officer of Oncology Care Systems for Siemens
Healthcare. "We believe our technologies complement one another ideally and once
fully integrated may lead to improved outcomes and a better quality-of-life for
all cancer patients." 

Also known as GPS for the Body®, Calypso`s proprietary technology utilizes
miniature implanted Beacon® 
      transponders to provide precise, continuous information on the location of
the tumor during external beam radiation therapy. Any movement by the patient,
including internal movement of the tumor, may cause the radiation to miss its
intended target and hit adjacent healthy tissue. In contrast to other tumor
targeting solutions, the Calypso System provides continuous tumor position
information, objectively and without ionizing radiation, thereby enabling an
increase in the radiation delivered to the tumor while reducing radiation
misapplied to normal tissue. 

"We use the Calypso System to ensure the precise delivery of radiation to our
prostate patients, even with reduced margins. As both a Siemens and Calypso
user, we are very encouraged by this new development agreement with Siemens,"
said Charles Enke, M.D., chairman of the department of radiation oncology at the
University of Nebraska Medical Center. 

At the 51st Annual Meeting of the American Society of Radiation Oncology,
currently underway in Chicago, Siemens Healthcare will showcase the first
targeted product of the MDA as a work-in-progress at booth 1829. 

In addition to the MDA with Siemens, Calypso also announced an MDA with Varian
Medical Systems earlier this year. 

About Calypso Medical

Calypso Medical Technologies, Inc. is a Seattle-based, privately held medical
device company. The Company`s proprietary tumor localization system utilizes
miniaturized implanted devices (Beacon® electromagnetic transponders) to
continuously, accurately and objectively track the location of tumors for
improved accuracy and management of radiation therapy delivery. The technology
is designed for body-wide cancers commonly treated with radiation therapy. The
products are FDA 510(k) cleared for use in the prostate and post-operative
prostatic bed. The Company has strategic relationships with Varian Medical
Systems, Siemens Healthcare, Elekta Corporation and Philips Medical. Additional
information can be found at 

About Siemens

The Siemens Healthcare Sector is one of the world's largest suppliers to the
healthcare industry and a trendsetter in medical imaging, laboratory
diagnostics, medical information technology and hearing aids. Siemens is the
only company to offer customers products and solutions for the entire range of
patient care from a single source - from prevention and early detection to
diagnosis, and on to treatment and aftercare. By optimizing clinical workflows
for the most common diseases, Siemens also makes healthcare faster, better and
more cost-effective. Siemens Healthcare employs some 49,000 employees worldwide
and operates in over 130 countries. In fiscal year 2008 (to September 30), the
Sector posted revenue of 11.2 billion euros and profit of 1.2 billion euros. For
further information please visit: 

* This technology is a concept device under development and not available for

Schwartz Communications
Krystin Hayward / Wendy Mejia, 781-684-0770
Calypso Medical
David Betz, 206-330-2621

Copyright Business Wire 2009

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.